Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...
In 2023, the American Academy of Pediatrics published a clinical practice guideline recommending weight-loss medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, as a supplement ...
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...
Its weight-loss drug policy would fall to Trump's pick for health secretary, Robert F Kennedy Jr, and Mehmet Oz, Trump's ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...
Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes.
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback